Premium
Pimecrolimus 1% cream for the treatment of rosacea
Author(s) -
KIM MoonBum,
KIM GunWook,
PARK HyunJe,
KIM HoonSoo,
CHIN HyunWoo,
KIM SuHan,
KIM ByungSoo,
KO HyunChang
Publication year - 2011
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.2011.01223.x
Subject(s) - rosacea , pimecrolimus , dermatology , medicine , erythema , surgery , calcineurin , transplantation , acne
Rosacea is a common inflammatory skin disorder; the pathogenesis is unclear. Various treatment options for rosacea are available, but most have limited effectiveness. The aim of this study was to investigate the efficacy and safety of 1% pimecrolimus cream for the treatment of rosacea. Thirty patients with rosacea were enrolled in this 4‐week, single‐center, open‐label study of 1% pimecrolimus cream. Patients were instructed to apply the cream to their faces twice daily and were not permitted to use any other agents. Clinical efficacy was evaluated by a rosacea grading system using photographic documentation and a mexameter. The 26 patients who completed the study experienced significantly reduced rosacea clinical scores from 9.65 ± 1.79 at baseline to 7.27 ± 2.11 at the end of treatment ( P < 0.05). The mexameter‐measured erythema index decreased significantly from 418.54 ± 89.56 at baseline to 382.23 ± 80.04 at week 4 ( P < 0.05). The side‐effects were mostly transient local irritations. The results of this study suggest that 1% pimecrolimus cream is an effective and well‐tolerated treatment for patients with mild to moderate inflammatory rosacea.